{
  "variants": [
    {
      "gene": "SNCA",
      "protein_change": "A30P",
      "variant_string_id": "SNCA A30P",
      "functional_evidence_aim": "Pathogenic",
      "acmg_flowchart": {
        "step_1": {
          "judgment": "Yes",
          "reasoning": "The paper explicitly links synuclein dysfunction (via PLD2 inhibition) to Parkinson's disease mechanisms."
        },
        "step_2": {
          "judgment": "Yes",
          "reasoning": "PLD2 inhibition assays are directly relevant to the disease mechanism (lipid signaling defects)."
        },
        "step_3": {
          "step_3a": {
            "judgment": "Yes",
            "reasoning": "Wild-type a-synuclein is used as a normal control, and mutants (A30P, A53T) are compared as abnormal controls."
          },
          "step_3c": {
            "judgment": "No",
            "reasoning": "No explicitly stated known pathogenic/benign variants are used as controls beyond wild-type and the mutants under study."
          }
        },
        "step_4": {
          "step_4b": {
            "judgment": "Max PS3_supporting",
            "reasoning": "Only 2 pathogenic variant controls (A30P, A53T) are used, which is <10."
          }
        }
      }
    },
    {
      "gene": "SNCA",
      "protein_change": "A53T",
      "variant_string_id": "SNCA A53T",
      "functional_evidence_aim": "Pathogenic",
      "acmg_flowchart": {
        "step_1": {
          "judgment": "Yes",
          "reasoning": "The paper connects synuclein dysfunction (via PLD2 inhibition) to Parkinson's disease mechanisms."
        },
        "step_2": {
          "judgment": "Yes",
          "reasoning": "PLD2 inhibition assays are directly relevant to the disease mechanism (lipid signaling defects)."
        },
        "step_3": {
          "step_3a": {
            "judgment": "Yes",
            "reasoning": "Wild-type a-synuclein is used as a normal control, and mutants (A30P, A53T) are compared as abnormal controls."
          },
          "step_3c": {
            "judgment": "No",
            "reasoning": "No explicitly stated known pathogenic/benign variants are used as controls beyond wild-type and the mutants under study."
          }
        },
        "step_4": {
          "step_4b": {
            "judgment": "Max PS3_supporting",
            "reasoning": "Only 2 pathogenic variant controls (A30P, A53T) are used, which is <10."
          }
        }
      }
    }
  ]
}